

Pharmasset - Tapping Both IFN and IFN-Free Opportunities

https://marketpublishers.com/r/P3C3DE0210FEN.html

Date: September 2011

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: P3C3DE0210FEN

Abstracts

Bristol-Myers announced topline PhII data of its once daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises the probability of success of the ongoing trial of PSI-7977 + BMS-790052 (PhIIb, Nucleotide + NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the approved drugs and other drugs in the pipeline, besides promising of IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled "Tapping Both IFN and IFN-Free Opportunities".



Contents

COMPANIES MENTIONED

Pharmasset



I would like to order

Product name: Pharmasset - Tapping Both IFN and IFN-Free Opportunities

Product link: https://marketpublishers.com/r/P3C3DE0210FEN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P3C3DE0210FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970